Untick a publication to hide it; your selections are stored in this browser. Journals, preprint servers, consumer brands and other high-volume feeds are off by default.
Daily edition · frozen at 7am Eastern
1984 stories from 409 outlets in 55 countries over the previous 24 hours; 18 were covered by more than one outlet. Permanent link: /edition/2026-11-11
Congo's Ebola outbreak has topped 11,000 cases, the government said Wednesday, a stark figure that underscores the severity of the situation as the country grapples with the relentless spread of the disease. (Image credit: Sebastien Kitsa Musayi)
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news that we’ll get straight into. The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease…
미국 식품의약국(FDA)이 지난 9일(현지시각) GLP-1 계열 의약품에 비동맥염성 전방 허혈성 시신경병증(NAION) 초래 가능성 표기를 의무화했다. 이와 관련해 식품의약품안전처는 GLP-1 계열 의약품의 허가변경 등을 검토한다는 방침이다.나이온(NAION)은 시신경 혈류 차단으로 인해 급격한 시력 저하가 나타나는 증상이다. 급성·무통성 시력 저하 또는 영구적 시력 상실 등을 초래할 수 있다.FDA는 이날 공식 홈페이지를 통해 GLP-1 계열 의약품 허가권자(제약사)가 NAION의 잠재적 위험 증가에 대한 정보를 제품 내 첨부문서
Oura, the smart ring maker that just over a month ago delayed plans to go public over market uncertainty, announced it will spend $625 million to acquire Counsel Health, a clinical artificial intelligence startup. Counsel Health is the maker of a chatbot that users can talk with about health…
El pasado lunes, la Administración de Alimentos y Medicamentos de EEUU (FDA, por sus siglas en inglés) informó a los pacientes y a los profesionales sanitarios sobre un posible aumento del riesgo de padecer una afección ocular grave asociada al uso de fármacos agonistas del receptor de GLP-1 …
The NCDC urged healthcare workers in public and private facilities to remain alert, ask patients about their travel history and possible exposure, and promptly notify public health authorities when Ebola is suspected.
ABD Gıda ve İlaç Dairesi (FDA), diyabet ve obezite tedavisinde kullanılan GLP-1 grubu ilaçların nadir görülen ancak kalıcı görme kaybına yol açabilen NAION riskini artırabileceğini belirterek prospektüslere uyarı eklenmesini zorunlu kıldı.
Stopping a GLP-1 treatment was linked to twice the combined risk of heart attack, stroke, or death for some people with type 2 diabetes, a study finds.Previous research indicated that glucagon-like peptide (GLP-1) receptor agonists can reduce heart attacks, strokes, and death in people with type 2…
In the meta-analysis, a few drugs stood out for offering greater effectiveness over time.
